Comparison of Antibiotic Susceptibility of Klebsiella Species Causing ‎Urinary Tract Infection in Iran and Other Countries around Asia ‎

Document Type : Research Paper

Authors

1 Imam Khomeini Hospital, Shirvan, North Khorasan University of Medical Sciences, Bojnurd, Iran

2 Islamic Azad University of Nishapur, Department of Biology, Nishapur, Iran

3 ‎Biotechnology Department, Iranian Research Organization for Science and Technology, IROST , Tehran, Iran‎

4 Clinical Microbiology Research Center, Ilam University of Medical Sciences sadeghifard@gmail.com

Abstract

This study aimed to evaluate the antibiotic-susceptibility pattern of Klebsiella pneumoniae causing urinary tract infection (UTI) in two geographical regions of Iran and then compare it to the rest of Iran and other countries. Over a year, from winter 2014 to winter 2015, 80 cases of Klebsiella were isolated from 2584 urine samples and identified using biochemical and microbiological tests. The disk diffusion method was used to determine antibiotic susceptibility based on the standard protocols provided by the CLSIs. The results of this study were compared with several reports from Iran and other countries, before the COVID-19 pandemic from 2007 to 2018. Based on the results of the antibiotic susceptibility of 80 isolated K. pneumoniae, amikacin (AN), Meropenem (MEN), gentamicin (GM), and ciprofloxacin (CP) were identified as the most sensitive antibiotics with 77.5%, 77%, 75%, and 58.75% sensitivity, respectively. A comparison of 17 report results showed imipenem (IPM) is the most sensitive antibiotic against the K. pneumoniae isolates, with a sensitivity range of 85% -100%. Followed by amikacin (AN), which was reported as the first or second antibiotic or third or fourth antibiotic in less than 30% of the cases. CP was reported as a second or third option in 22% of the cases. This study evaluated the sensitivity pattern of K. pneumoniae to antibiotics, and the results show that it has the potential to be applied to further studies and related programs, including periodic screening, regional screening, and revision in therapeutic approaches.

Keywords

Main Subjects

Microbiology, Metabolites and Biotechnology
Volume 6, Issue 2
November 2023
Pages 53-62

Files

Share

How to cite

Statistics